peoplePerson
Drew Weissman
Drew Weissman is the Nobel laureate whose modified-mRNA discovery underlies mRNA vaccines and now in vivo CAR-T.
With Katalin Karikó, discovered that nucleoside modification lets mRNA evade innate immune sensing (Nobel Prize 2023). His lab works on targeted LNPs, including in vivo T-cell engineering that seeded Capstan.
Role
Roberts Family Professor in Vaccine Research; Director, Penn Institute for RNA Innovation
Specialisms
mRNA therapeuticsLipid nanoparticlesIn vivo cell engineering
Profiles
Pages like this
not linked directly; found by shared links- PersonBruce L. Levine
Shares In vivo CAR-T, Abramson Cancer Center, University of Pennsylvania.
- CompanyInterius BioTherapeutics
Shares In vivo CAR-T, Abramson Cancer Center, University of Pennsylvania.
- TechnologyEngineered exosomes as drug carriers
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.
- TechnologySelf-amplifying and circular RNA therapeutics
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.